Lilly prices new clot-buster at 31% premium

Eli Lilly launched its new blood thinner in its first market today: the U.K. Effient/Efient (prasugrel) is priced 31 percent higher than its rival Plavix, the world's leading anticoagulant marketed by Bristol-Myers Squibb and Sanofi Aventis. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.